Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 20

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 20
---
 Company, business planning, acquiring rights
to technologies, and identifying potential product candidates. In addition, we have limited human resources to help us achieve our goals.
Consequently, any predictions made about our future success or viability based on our short operating history to date may not be as accurate
as they could be if we had a longer and more established operating history. In addition, as an early-stage business, we may encounter
unforeseen expenses, difficulties, complications, delays and other known and unknown factors.

Business interruptions resulting from the coronavirus
disease (COVID-19) outbreak or similar public health crises could cause a disruption of the development of product candidates and adversely
impact our business.

In March 2020, the World Health Organization declared
the novel coronavirus disease (COVID-19) outbreak a global pandemic. To limit the spread of COVID-19, governments have taken various actions
including the issuance of stay-at-home orders and physical distancing guidelines. Accordingly, businesses have adjusted, reduced or suspended
operating activities. We may experience disruptions as a result of COVID-19, any variants of COVID-19, or any other pandemic that could
severely impact our business and planned clinical trials, including:

    ·
    delays or difficulties in planned clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

    ·
    delays or difficulties in enrolling patients in our planned clinical trials and further incurrence of additional costs as a result of preclinical study and clinical trial delays and adjustments;

    ·
    challenges related to ongoing and increased operational expenses related to any pandemic;

    ·
    diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;

    ·
    interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;

    ·
    limitations in resources that would otherwise be focused on the conduct of our business or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed “Stay-at-Home” orders or similar working restrictions;

    ·
    delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;

    ·
    delays in preclinical and clinical sites receiving the supplies and materials needed to conduct our planned clinical trials;

    ·
    interruption in global shipping that may affect the